Hims & Hers Health trades at $33.39 per share and has stayed right on track with the overall market, gaining 9.6% over the ...

Hims & Hers reported a surge in sales in the first quarter of 2025, up 111% year over year at $586 million. (Wall Street only wanted $539 million, but isn't complaining.) Subscribers grew only 38% ...

Hims & Hers Health ( HIMS) stock saw it’s shares drop more than 30% during trading on Monday. The sharp decline was one of the steepest one-day drops in the stock’s history. HIMS shares fell after ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no longer ...

Hims & Hers Health, Inc. remains a Buy, with a solid bottom forming despite recent margin and revenue challenges. HIMS is pivoting from compounded GLP-1s to branded partnerships with NVO and LLY, ...

Is HIMS a good stock to buy? We came across a bullish thesis on Hims & Hers Health, Inc. on TopSecretStocks’s Substack by Simon. In this article, we will summarize the bulls’ thesis on HIMS. Hims & ...

Recent discussions on X about Hims & Hers Health (HIMS) have been buzzing with interest, particularly around the company's innovative telehealth model and its rapid revenue growth. Many users have ...

The company expects to leverage its specialty-specific marketing efforts to drive growth in both new and tenured categories. Continued investment in automation and pharmacy infrastructure is ...

Hims & Hers Health stock might be falling out of favor on Wall Street, but one prominent insider is using the steep selloff to flip from seller to buyer.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.